- Home
- OFS vs IKT Comparison
OFS vs IKT Comparison
Compare OFS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- IKT
- Stock Information
- Founded
- OFS 2001
- IKT 2008
- Country
- OFS United States
- IKT United States
- Employees
- OFS N/A
- IKT N/A
- Industry
- OFS Finance/Investors Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- OFS Finance
- IKT Health Care
- Exchange
- OFS Nasdaq
- IKT Nasdaq
- Market Cap
- OFS 95.6M
- IKT 111.8M
- IPO Year
- OFS 2012
- IKT 2020
- Fundamental
- Price
- OFS $5.00
- IKT $1.53
- Analyst Decision
- OFS
- IKT Hold
- Analyst Count
- OFS 0
- IKT 1
- Target Price
- OFS N/A
- IKT N/A
- AVG Volume (30 Days)
- OFS 115.3K
- IKT 109.4K
- Earning Date
- OFS 10-30-2025
- IKT 11-14-2025
- Dividend Yield
- OFS 13.60%
- IKT N/A
- EPS Growth
- OFS N/A
- IKT N/A
- EPS
- OFS 0.24
- IKT N/A
- Revenue
- OFS $42,970,000.00
- IKT N/A
- Revenue This Year
- OFS N/A
- IKT N/A
- Revenue Next Year
- OFS N/A
- IKT N/A
- P/E Ratio
- OFS $20.74
- IKT N/A
- Revenue Growth
- OFS N/A
- IKT N/A
- 52 Week Low
- OFS $5.00
- IKT $1.33
- 52 Week High
- OFS $9.80
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- OFS 22.63
- IKT 47.90
- Support Level
- OFS $5.07
- IKT $1.55
- Resistance Level
- OFS $5.53
- IKT $1.67
- Average True Range (ATR)
- OFS 0.38
- IKT 0.13
- MACD
- OFS -0.05
- IKT 0.01
- Stochastic Oscillator
- OFS 0.00
- IKT 51.16
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.